Introduction
multiple myeloma, ovarian cancer, cancer nanomedicine, breast cancer, toxicity, cancer, Breast cancer, Kaposi’s sarcoma, lung cancer, deaths
MULTIPLE MYELOMA, OVARIAN CANCER, BREAST CANCER, CANCER, BREAST CANCER, LUNG CANCER, ACQUIRED IMMUNE DEFICIENCY SYNDROME
Breast cancer has become the most commonly diagnosed cancer globally in 2020, surpassing lung cancer (11.4%), with an estimated 2,261,419 new cases (11.7%), and the fourth leading cause (6.9%) of cancer-related deaths worldwide, with an estimated 684,996 new deaths in 2020 [During the past 70 years, the highest number of new drugs for breast cancer was approved [Pegylated liposomal doxorubicin (PLD), developed in an attempt to reduce the toxicity profile of conventional doxorubicin while preserving its anti-tumor efficacy, became the first United States Food and Drug Administration -approved cancer nanomedicine in 1994, and it is currently indicated for advanced ovarian cancer, acquired immune deficiency syndrome (AIDS)-related Kaposi’s sarcoma, and multiple myeloma in the United States [Additionally, the recommended dose of PLD is 50 mg/mDuomeisuWe conducted a prospective, single-center, open-label, phase II study to evaluate the efficacy and safety of Duomeisu